Chimeric antigen receptor T-cell therapy in dermatologic autoimmunity: Mechanisms, applications, and future directions.

Autoimmune skin diseases impose substantial morbidity despite therapeutic advances, with current treatments requiring lifelong immunosuppression without eliminating pathogenic immune responses. Chimeric antigen receptor (CAR) T-cell therapy is a promising approach to achieve durable remission through the targeted elimination of immune cells followed by immune reconstitution. This review examines CAR-T therapy in dermatologic autoimmunity, discussing CD19- and B-cell maturation antigen-targeted approaches alongside precision strategies such as chimeric autoantibody receptor T cells. Early clinical data demonstrate drug-free remissions with favorable safety profiles, although longer follow-up and randomized trials are needed to establish durability and comparative effectiveness before CAR-T therapy can fulfill its potential.